Transforming Cardiorenal Care: Timely Diagnosis and Guideline-driven Management of Heart Failure and Chronic Kidney Disease

This activity presents a recorded symposium from the 20th Annual CMHC, focusing on the challenges of chronic kidney disease (CKD) and heart failure (HF), while highlighting the significance of cardio-kidney-metabolic health. Experts from nephrology, cardiology, and endocrinology backgrounds gathered to discuss key topics, including early detection of CKD, the proven advantages of SGLT-2 inhibitors for better cardiorenal outcomes, and emerging treatments with cardiorenal-metabolic benefits. The conversation also emphasized the importance of multidisciplinary care, showcasing collaboration among endocrinologists, cardiologists, nephrologists, and primary care providers to enhance patient outcomes. After this session, participants will be equipped to optimize treatment strategies based on the most recent evidence and guidelines to better help patients with HF, CKD, or at risk for cardiorenal disease.

Target Audience

The educational design of this activity addresses the needs of U.S. based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), pharmacists, and other advanced practice providers.

Learning Objectives

After completing this activity, the participant should be better able to: 

  • Recognize the burden of chronic kidney disease (CKD) and heart failure while discussing the importance of addressing cardio-kidney-metabolic health 
  • Identify early signs and diagnostic criteria for CKD to facilitate timely identification and interventions 
  • Assess the latest cardiovascular and kidney outcomes associated with SGLT-2 inhibitors, emphasizing their role in improving cardiorenal health in patients with and without diabetes. 
  • Integrate a multidisciplinary collaborative care model that includes endocrinologists, cardiologists, nephrologists, and primary care physicians to deliver optimal patient care for individuals with cardiovascular, renal, and metabolic comorbidities.  
  • Select individualized treatment regimens based on the latest evidence and guideline recommendations to optimize GDMT in patients with HF or CKD or cardiorenal risk with or without T2DM 
Course summary
Available credit: 
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Course opens: 
02/24/2026
Course expires: 
02/24/2027
Rating: 
0

Pam R. Taub MD, FACC, FASPC (Chair) 
Founder and Director of Step Family Cardiac Rehabilitation and Wellness Center  
Step Family Director's Endowed Chair  
Director of Preventive Cardiology  
Professor of Medicine  
UC San Diego Health System 

 

Jennifer Green, MD 
Division of Endocrinology  
Duke Clinical Research Institute  
Duke University School of Medicine 

 

Sylvia E. Rosas, MD, MSCE  
Kidney and Hypertension Unit  
Joslin Diabetes Center  
Associate Professor of Medicine  
Harvard Medical School 

 

Chiadi Ndumele, MD, PhD, MHS 
Associate Professor of Medicine  
Director of Obesity and Cardiometabolic Research  
Division of Cardiology,  
Johns Hopkins University  
Chair, AHA Council on Lifestyle and Cardiometabolic Health 

ESTIMATED TIME TO COMPLETE ACTIVITY
1.5 hours

EDUCATIONAL GRANT SUPPORT

Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.  

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Cardiometabolic Health Congress (CMHC).  Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

Partners designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

Partners designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-091-H01-P Type of activity: Application

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

DIETITIAN CONTINUING EDUCATION

This program offers 1.5 CPEUs for dietitians.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 0.75 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from February 24, 2026 through February 24, 2027.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected]. For additional information about the accreditation of this activity, please visit https://partnersed.com

DISCLOSURES

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Taub, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: Amgen, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Medtronic Cleerly, Esperion, Edwards, Lexicon, Jazz Pharma, Merck, Roche 

Dr. Green, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Vertex, Valo, Lilly, Mineralys, Novo Nordisk, Idorsia, Zealand 
  • Researcher: Boehringer Ingelheim, Lilly, Merck, Roche, Bluedrop 

Dr. Ndumele, faculty for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose. 

Dr. Rosas, faculty for this educational activity, discloses the following:

  • Researcher: Bayer, AstraZeneca, Prokidney 
  • Consultant, Advisor, Speaker: Travere 
  • Independent Contractor: Dynamed 

DISCLOSURE OF UNLABELED USE 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

DISCLAIMER 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Available Credit

  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.